Ovid Therapeutics Inc. filings document a Nasdaq-listed biopharmaceutical company focused on small-molecule medicines for CNS disorders involving neuronal hyperexcitability. Its regulatory record includes 8-K disclosures for clinical program updates, operating and financial results, leadership and compensation arrangements, Nasdaq compliance, and capital-structure events involving common stock, preferred stock, warrants and pre-funded warrants.
Proxy statements disclose board and executive governance, equity compensation, shareholder meeting proposals, authorized-share matters, and stockholder votes required under Nasdaq rules for securities issuances. The filings also record material agreements, risk and governance subjects, and exhibits related to the company’s OV350, OV4071 and OV329 development programs.
Ovid Therapeutics is registering for resale 29,856,031 shares of common stock originally issued in a March 2026 private placement, including 10,701,710 shares issuable upon exercise of Pre-Funded Warrants.
The registration covers resale by the private placement investors and their permitted transferees; Ovid will not receive proceeds from those resale transactions, although it will receive nominal proceeds if Pre-Funded Warrants are exercised for cash. The percentages shown in the selling-stockholder table use 173,037,131 shares outstanding as of April 17, 2026.
Ovid Therapeutics Inc. registered 29,856,031 shares of common stock for resale by selling stockholders pursuant to a March 17, 2026 private placement. The resale covers 19,154,321 issued shares and 10,701,710 shares issuable upon exercise of pre-funded warrants.
The registration is being filed to satisfy contractual registration rights and does not require the selling stockholders to sell shares. Ovid will not receive proceeds from resales by the selling stockholders; the company received approximately $60.0 million gross from the Private Placement and would receive nominal proceeds only upon any cash exercise of the pre-funded warrants. Common stock trades on Nasdaq under OVID; last reported sale price was $2.91 on April 17, 2026.
Ovid Therapeutics Inc. reported that its Series A Warrants issued in an October 2025 private placement expired on April 17, 2026. Holders elected to exercise warrants into 33,597,860 common shares at $1.40 per share and 4,883,464 pre-funded warrants at $1.399 per warrant.
These exercises covered most of the 38,481,325 common shares underlying the Series A Warrants and generated approximately $53.9 million in gross cash proceeds for the company.
PAPADOPOULOS STELIOS reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics director Stelios Papadopoulos received a stock-based compensation award in the form of restricted stock units. The grant covers 17,578 shares of common stock valued at $2.56 per share, replacing a $45,000 annual cash retainer. The RSUs vest 25% at grant and 25% on each of June 30, 2026, September 30, 2026 and December 31, 2026, contingent on continued board service. After this award, he holds 217,578 common shares directly.
Friedman Bart reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics Inc. reported that director Bart Friedman received a grant of 8,789 shares of Common Stock as a restricted stock unit (RSU) award, valued at $22,500 based on a reference price of $2.56 per share.
The RSU award was issued under Ovid’s Non-Employee Director Compensation Policy in lieu of 50% of his annual cash retainer for Board service. The RSUs vest 25% upon grant and 25% on each of June 30, 2026, September 30, 2026, and December 31, 2026, conditioned on his continuous service.
Fitzgerald Kevin Joseph reported acquisition or exercise transactions in this Form 4 filing.
Ovid Therapeutics Inc. director Kevin Joseph Fitzgerald received a grant of 17,578 shares of common stock as a restricted stock unit (RSU) award valued at $45,000, in lieu of his annual cash retainer for board service. The RSUs were granted at $2.56 per share and vest 25% immediately, with the remaining 25% tranches scheduled on June 30, 2026, September 30, 2026, and December 31, 2026, subject to his continued service. Following this compensation award, he directly holds 17,578 shares reported in this filing.
Ovid Therapeutics Executive Chairman Jeremy M. Levin exercised a Series A warrant to acquire 47,333 shares of Common Stock at $1.40 per share. Following the exercise, he directly holds 3,735,048 shares of Common Stock.
The filing also reports 35,461 shares of Common Stock held indirectly through Divo Holdings, LLC, managed by Levin’s spouse. Levin expressly disclaims beneficial ownership of the shares held by Divo.
Ovid Therapeutics Inc. is a Delaware-based biopharmaceutical company focused on small molecule medicines for brain disorders driven by neuronal hyperexcitability, including epilepsies, psychoses, schizophrenia and mood disorders. Its strategy targets fundamental CNS mechanisms such as GABA-aminotransferase inhibition and direct activation of potassium-chloride cotransporter 2 (KCC2).
The lead seizure program, OV329, is a next-generation GABA-AT inhibitor intended as a safer, more potent alternative to vigabatrin for drug‑resistant epilepsies, tuberous sclerosis complex seizures and infantile spasms. Phase 1 data in healthy volunteers showed favorable safety, biomarker evidence of increased GABAergic activity and no observed retinal accumulation in animal models at expected therapeutic doses.
Ovid’s KCC2 portfolio, in‑licensed from AstraZeneca, includes more than 100 small molecules and the oral candidate OV4071, with a Phase 1 trial planned for the second quarter of 2026 to explore applications in psychosis and mood disorders. The company also holds economic rights from a ganaxolone license to Immedica via Marinus, including a $7.0 million cash payment replacing royalties. As of June 30, 2025, non‑affiliate common stock market value was about $22.2 million, and as of March 16, 2026 there were 131,874,634 common shares outstanding.
Ovid Therapeutics Inc. is a Delaware-based biopharmaceutical company focused on small molecule medicines for brain disorders driven by neuronal hyperexcitability, including epilepsies, psychoses, schizophrenia and mood disorders. Its strategy targets fundamental CNS mechanisms such as GABA-aminotransferase inhibition and direct activation of potassium-chloride cotransporter 2 (KCC2).
The lead seizure program, OV329, is a next-generation GABA-AT inhibitor intended as a safer, more potent alternative to vigabatrin for drug‑resistant epilepsies, tuberous sclerosis complex seizures and infantile spasms. Phase 1 data in healthy volunteers showed favorable safety, biomarker evidence of increased GABAergic activity and no observed retinal accumulation in animal models at expected therapeutic doses.
Ovid’s KCC2 portfolio, in‑licensed from AstraZeneca, includes more than 100 small molecules and the oral candidate OV4071, with a Phase 1 trial planned for the second quarter of 2026 to explore applications in psychosis and mood disorders. The company also holds economic rights from a ganaxolone license to Immedica via Marinus, including a $7.0 million cash payment replacing royalties. As of June 30, 2025, non‑affiliate common stock market value was about $22.2 million, and as of March 16, 2026 there were 131,874,634 common shares outstanding.
Ovid Therapeutics entered a private placement financing, agreeing to sell 19,154,321 common shares at $2.01 and pre-funded warrants for up to 10,701,710 shares at $2.009 each, for expected gross proceeds of $60.0 million before fees. The company signed a registration rights agreement to register these securities for resale shortly after closing.
Ovid reported favorable 7 mg Phase 1 data for OV329 and plans a Phase 2 trial in treatment-resistant focal onset seizures plus new studies in tuberous sclerosis complex seizures and infantile spasms. OV4071 received clearance to begin Phase 1 in Australia, triggering a 30-day exercise window for Series A warrants that could add up to $53.9 million in gross proceeds.
As of December 31, 2025, Ovid held $90.4 million in cash, cash equivalents and marketable securities and reported 2025 revenue of $7.3 million, total operating expenses of $49.7 million and a net loss of $17.4 million, while fourth quarter 2025 net income was $9.7 million driven mainly by a fair value gain on an equity investment.
Ovid Therapeutics entered a private placement financing, agreeing to sell 19,154,321 common shares at $2.01 and pre-funded warrants for up to 10,701,710 shares at $2.009 each, for expected gross proceeds of $60.0 million before fees. The company signed a registration rights agreement to register these securities for resale shortly after closing.
Ovid reported favorable 7 mg Phase 1 data for OV329 and plans a Phase 2 trial in treatment-resistant focal onset seizures plus new studies in tuberous sclerosis complex seizures and infantile spasms. OV4071 received clearance to begin Phase 1 in Australia, triggering a 30-day exercise window for Series A warrants that could add up to $53.9 million in gross proceeds.
As of December 31, 2025, Ovid held $90.4 million in cash, cash equivalents and marketable securities and reported 2025 revenue of $7.3 million, total operating expenses of $49.7 million and a net loss of $17.4 million, while fourth quarter 2025 net income was $9.7 million driven mainly by a fair value gain on an equity investment.